Biotechnology company Enzo Biochem Inc. said Wednesday it entered a deal to let Cancer Genetics Inc. use its dye labeling technology.
Terms of the deal weren't disclosed.
Cancer Genetics, a privately owned company based in Rutherford, N.J., makes products that help diagnose and treat cancer based on the genetic profile of patients. The company will use Enzo's fluorescent dye labeling to improve the DNA sequence detection abilities of its products.
Shares of Enzo advanced 7 cents to $6.32 in early afternoon trading.